Table 4.
Summary of results from all subgroup analyses.
| Indicators | Subgrouped by | The number of studies | Effect size | 95% CI | I2 (%) | P for between subgroup heterogeneity |
|---|---|---|---|---|---|---|
| Major complications | Types of study | – | – | – | – | 0.33 |
| RCT | 4 | 0.86 | 0.68, 1.09 | 56 | – | |
| MS | 3 | 0.63 | 0.36, 1.11 | 0 | – | |
| Total biliary complications | Types of study | – | – | – | – | 0.61 |
| RCT | 5 | 0.71 | 0.54, 0.93 | 0 | – | |
| MS | 6 | 0.79 | 0.58, 1.08 | 0 | – | |
| Donor type | – | – | – | – | 0.99 | |
| DCD | 4 | 0.74 | 0.59, 0.94 | 0 | – | |
| DBD | 7 | 0.74 | 0.51, 1.08 | 0 | – | |
| HAT | Types of study | – | – | – | – | 0.46 |
| RCT | 4 | 1.18 | 0.38, 3.63 | 0 | – | |
| MS | 2 | 0.54 | 0.09, 3.10 | 0 | – | |
| Donor type | – | – | – | – | 0.53 | |
| DCD | 3 | 0.70 | 0.19, 2.53 | 0 | – | |
| DBD | 3 | 1.29 | 0.32, 5.13 | 21 | – | |
| NAS | Types of study | – | – | – | – | 0.92 |
| RCT | 2 | 0.35 | 0.14, 0.86 | 0 | – | |
| MS | 5 | 0.33 | 0.15, 0.72 | 0 | – | |
| Donor type | – | – | – | – | 0.28 | |
| DCD | 4 | 0.29 | 0.15, 0.57 | 0 | – | |
| DBD | 3 | 0.65 | 0.18, 2.32 | 0 | – | |
| PNF | Types of study | – | – | – | – | 0.59 |
| RCT | 4 | 0.40 | 0.10, 1.68 | 0 | – | |
| MS | 6 | 0.67 | 0.22, 2.06 | 3 | – | |
| Donor type | – | – | – | – | 0.30 | |
| DCD | 4 | 0.26 | 0.05, 1.50 | 0 | – | |
| DBD | 6 | 0.77 | 0.27, 2.21 | 0 | – | |
| EAD | Types of study | – | – | – | – | 0.41 |
| RCT | 5 | 0.50 | 0.38, 0.66 | 16 | – | |
| MS | 5 | 0.62 | 0.41, 0.93 | 0 | – | |
| Donor type | – | – | – | – | 0.67 | |
| DCD | 3 | 0.58 | 0.38, 0.87 | 0 | – | |
| DBD | 7 | 0.52 | 0.39, 0.69 | 23 | – | |
| Acute rejection | Donor type | – | – | – | – | 0.07 |
| DCD | 2 | 0.31 | 0.13, 0.75 | 68 | – | |
| DBD | 3 | 0.90 | 0.43, 1.91 | 0 | – | |
| Patient survival | Types of study | – | – | – | – | 0.75 |
| RCT | 2 | 0.75 | 0.27, 2.07 | 0 | – | |
| MS | 3 | 0.58 | 0.18, 1.93 | 0 | – | |
| Graft survival | Types of study | – | – | – | – | 0.92 |
| RCT | 3 | 0.37 | 0.16, 0.85 | 0 | – | |
| MS | 4 | 0.39 | 0.17, 0.88 | 0 | – | |
| Donor type | – | – | – | – | 0.33 | |
| DCD | 2 | 0.23 | 0.07, 0.80 | 0 | – | |
| DBD | 5 | 0.46 | 0.24, 0.90 | 0 | – | |
| Hospital stay | Types of study | – | – | – | – | 0.77 |
| RCT | 4 | −1.54 | −3.37, 0.30 | 67 | – | |
| MS | 5 | −1.06 | −3.64, 1.53 | 0 | – | |
| Donor type | – | – | – | – | 0.50 | |
| DCD | 3 | −1.94 | −4.14, 0.27 | 0 | – | |
| DBD | 6 | −0.90 | −2.94, 1.14 | 58 | – | |
| ICU stay | Types of study | – | – | – | – | 0.70 |
| RCT | 5 | 0.21 | −0.19, 0.61 | 56 | – | |
| MS | 4 | −0.01 | −1.07, 1.05 | 0 | – | |
| Donor type | – | – | – | – | 0.17 | |
| DCD | 3 | 0.55 | −0.09, 1.19 | 0 | – | |
| DBD | 6 | −0.00 | −0.46, 0.46 | 38 | – | |
| Renal replacement therapy | Types of study | – | – | – | – | 0.30 |
| RCT | 2 | 0.75 | 0.38, 1.47 | 0 | – | |
| MS | 5 | 1.19 | 0.68, 2.08 | 1 | – | |
| Donor type | – | – | – | – | 0.30 | |
| DCD | 4 | 1.13 | 0.68, 1.89 | 27 | – | |
| DBD | 3 | 0.68 | 0.31, 1.53 | 0 | – |
DBD, donors after brain death; DCD, donors after cardiac death; EAD, early allograft dysfunction; HAT, hepatic artery thrombosis; ICU, intensive care unit; MS, matched study; NAS, non-anastomotic biliary stricture; PNF, primary non-function; RCT, randomized controlled trial.